Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2026)
Solid Biosciences (SLDB) posted Income from Continuing Operations of 60675000.0 for Q1 2026, down 17.28% sequentially from 51735000.0 in Q4 2025, and down 60.13% YoY from 152167390.3 in Q1 2025.
Powered by 
Analysis
Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Solid Biosciences has reported Income from Continuing Operations for 10 years, with the latest figure at 60675000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 60.13% year-over-year to 60675000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 201739000.0 (down 43.4% YoY) and the FY2025 annual result came in at 359739000.0, down 43.35% from the prior year.
- Income from Continuing Operations declined to 60675000.0 in Q1 2026 per SLDB's latest filing, from 51735000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 20592000.0 in Q3 2022 and troughed at 196598000.0 in Q4 2022.
- A 5-year average of 43654000.0 and a median of 32078000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 87.45% in 2023, then sank 70.15% in 2024.
- Over 5 years, Income from Continuing Operations stood at 196598000.0 in 2022, then soared by 87.45% to 24667000.0 in 2023, then tumbled by 70.15% to 41970000.0 in 2024, then declined by 23.27% to 51735000.0 in 2025, then declined by 17.28% to 60675000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 60675000.0, 51735000.0, and 47129000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | -54.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -54.16 Mn |
| Mar 31, 2026 | -57.37 Mn |
| Dec 31, 2025 | -47.36 Mn |
| Sep 30, 2025 | -45.14 Mn |
| Jun 30, 2025 | -38.79 Mn |
| Mar 31, 2025 | -40.17 Mn |
| Dec 31, 2024 | -38.05 Mn |
| Sep 30, 2024 | -32.94 Mn |
| Jun 30, 2024 | -27.89 Mn |
| Mar 31, 2024 | -26.98 Mn |
| Dec 31, 2023 | -20.61 Mn |
| Sep 30, 2023 | -21.26 Mn |
| Jun 30, 2023 | -26.95 Mn |
| Mar 31, 2023 | -32.08 Mn |
| Dec 31, 2022 | -33.03 Mn |
| Sep 30, 2022 | -20.40 Mn |
| Jun 30, 2022 | -25.09 Mn |
| Mar 31, 2022 | -25.32 Mn |
| Dec 31, 2021 | -18.65 Mn |
| Sep 30, 2021 | -18.03 Mn |